Cannabis Science Set to Integrate Its Sponsored Research In Nigeria to Include Its U.S. Patent Number 9,763,991 for Compositions of Cannabinol (CBN) for Treatment of Various Neurological Conditions

IRVINE, CA, Feb. 25, 2019 (GLOBE NEWSWIRE) — CANNABINOL (CBN) Pre-Clinical Work and Animal Studies Underway, and Protocols for Clinical Studies Under Development   via NEWMEDIAWIRE — Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it intends to expand the scope of its sponsored research in Nigeria to include neurological conditions, including Post-Traumatic Stress Disorder (PTSD).